Showing 2131-2140 of 4063 results for "".
- AAO: ACA’s Medicaid Expansion Failed to Improve Diabetic Dilated Eye Exam Rates Long-Termhttps://modernod.com/news/aao-acas-medicaid-expansion-failed-to-improve-diabetic-dilated-eye-exam-rates-long-term/2478111/New research shows significantly more people with diabetes got their critical annual dilated eye exam during the first 2 years following Medicaid expansion under the under the Affordable Care Act (ACA). However, this encouraging increase in the exam rate did not persist beyond 2 years. The study’
- Pfizer, BioNTech’s mRNA-Based COVID-19 Vaccine Shows Promise in Second Studyhttps://modernod.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/Pfizer and BioNTech announced that the most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralising titers after the second dose in an ongoing phase 1/2 study in Germany. The results, which were publ
- Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assayhttps://modernod.com/news/quidel-receives-emergency-use-authorization-for-molecular-covid-19-diagnostic-assay/2477407/Quidel, a provider of rapid diagnostic testing solutions, announced that the company has received Emergency Use Authorization (EUA) from the FDA to market its Lyra SARS-CoV-2 Assay, a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or
- AAO Alert: Coronavirus Update for Ophthalmologistshttps://modernod.com/news/aao-alert-coronavirus-updates-for-ophthalmologists/2477347/The Academy is sharing important ophthalmology-specific information related to the novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was previously known by the provisional name 2019-nCoV. The highly contagious virus can cause a severe respirato
- Aura Biosciences to Present Long-Term Clinical Data for AU-011 at ASRShttps://modernod.com/news/aura-biosciences-to-present-long-term-clinical-data-for-au-011-at-asrs/2476767/Aura Biosciences announced that 2-year clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the Am
- Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasishttps://modernod.com/news/eyenovia-announces-confirmatory-results-from-second-microstat-phase-3-registration-study-for-mydriasis/2476266/Eyenovia announced positive results from its second MicroStat phase 3 study, MIST-2, which examined the safety and efficacy of the company’s first-in-class MicroStat fixed-combination formulation for pharmacologic mydriasis. The MIST-2 study was a US-based, multicenter, randomized, double-
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Genentech Presents Longer-Term Efficacy and Safety for Enspryng in NMOSDhttps://modernod.com/news/genentech-presents-longer-term-efficacy-and-safety-for-enspryng-in-nmosd/2480720/Genentech is presenting a range of new data from its neuroscience portfolio at the AAN 2022 Annual Meeting (April 2-7 in Seattle), including
- Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-12-month-data-of-investigational-rpgr-gene-therapy-shows-statistically-significant-and-continued-vision-improvement-in-patients-with-xlrp/2478557/The Janssen Pharmaceutical Companies of Johnson & Johnson announced new 12-month data from the ongoing phase 1/2 trial (